Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03426878 · ClinicalTrials.gov registry record · NA
Cancer Health Assessments Reaching Many
A NA study, sponsored by Kaiser Permanente.
- Completed
- Registry status
- NA
- Development phase
- 967
- Enrollment target
NCT03426878 is a NA study that has completed, run by Kaiser Permanente. The registered enrollment target is 967 participants.
The verdict
NCT03426878, a NA study, has completed, sponsored by Kaiser Permanente.
- COMPLETED
- Registry status
- NA
- Development phase
- 967 participants
- Enrollment target
Study Summary
The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk assessment program in healthy 18-49 year-olds in primary care settings within a vertically integrated health delivery system (Kaiser Permanente) and a federal qualified health center (Denver Health). The investigators will assess clinical exome sequencing implementation and interpretation, as well as tailored interactions for low health literacy including a contextualized consent process, and a modified approach to results disclosure and genetic counseling. The investigators will also assess the clinical utility (healthcare utilization and adherence to recommended care) and personal utility of primary and additional results from clinical exome sequencing, and evaluate the ethical and policy implications of considering personal utility of genomic information decisions for health care coverage.
Interventions
- OTHER Modified genetic counseling
- OTHER Traditional genetic counseling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 967 participants |
| Start Date | 2018-08-15 |
| Est. Completion | 2022-02-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03426878
The ClinicalTrials.gov registry entry for NCT03426878 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 967 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Modified genetic counseling is the first listed.
NCT03426878 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03426878 about?
NCT03426878 is a clinical study titled "Cancer Health Assessments Reaching Many". The CHARM (Cancer Health Assessment Reaching Many) study will assess the utility of clinical exome sequencing and how it affects care in diverse populations. The study population includes adults at risk for hereditary cancer syndromes. The primary objective is to implement a hereditary cancer risk ...
What is the current status of trial NCT03426878?
This trial is currently completed. It is a NA study. The enrollment target is 967 participants. The study started on 2018-08-15. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT03426878?
The interventions under investigation include: Modified genetic counseling (OTHER), Traditional genetic counseling (OTHER).
Who is sponsoring clinical trial NCT03426878?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.